 |
Haleon plc: Historic Proforma Category Financial Performance
7 July 2025: Haleon plc (the "Company" or "Haleon") today releases the historical proforma category financial information, aligned with the announcement at the Capital Markets Day on 1 May 2025. Haleon will now be reporting six categories: Oral Health; Vitamins, Minerals, and Supplements (VMS); Pain Relief; Respiratory Health; Digestive Health; and Therapeutic Skin Health and Other.
Compared to previous reporting, the new structure:
|
● |
Splits out Digestive Health & Other into Digestive Health, and Therapeutic Skin Health and Other |
|
● |
Smokers Health which had previously been reported as part of Digestive Health and Other will now be included in Respiratory Health |
|
● |
There are no changes to other categories not outlined above
|
We will begin reporting in this new category structure at our 2025 Half Year Results on 31 July 2025. The purpose of this change is to better align Haleon's reporting with the strategic opportunities ahead as well as improve visibility of Haleon's financial performance. Haleon's geographical split remains unchanged.
Detailed below is the quarterly pro-forma actual and comparative financial information on this basis. Definitions for non-IFRS measures can be found on pages 19-27 in Haleon's 2024 Full Year Results, and pages 43-50 in Haleon's Annual Report and Form 20-F 2024.
|
Restated FY 2023 and FY 2024 reported revenue, organic revenue growth, and reported revenue growth by category (unaudited) |
|||||||
|
|
2023 |
|
2024 |
||||
|
|
£m revenue |
Organic Revenue Growth |
Reported Revenue Growth |
|
£m revenue |
Organic Revenue Growth |
Reported Revenue Growth |
|
Oral Health |
3,136 |
10.6% |
6.1% |
|
3,312 |
9.6% |
5.6% |
|
VMS |
1,640 |
0.9% |
-2.1% |
|
1,696 |
7.6% |
3.4% |
|
Pain Relief |
2,652 |
7.4% |
4.0% |
|
2,564 |
0.1% |
-3.3% |
|
Respiratory Health |
2,244 |
11.7% |
8.2% |
|
2,122 |
1.0% |
-5.4% |
|
Digestive Health |
1,012 |
5.8% |
1.9% |
|
1,029 |
5.5% |
1.7% |
|
Therapeutic Skin Health and Other |
618 |
8.8% |
1.5% |
|
510 |
9.8% |
-17.5% |
|
TOTAL |
11,302 |
8.0% |
4.1% |
|
11,233 |
5.0% |
-0.6% |
|
Restated quarterly reported revenue by category (unaudited) |
|
|
|
|
|
|
|
|
|||||
|
|
2023 |
|
2024 |
|
2025 |
||||||||
|
£m |
Q1 |
Q2 |
Q3 |
Q4 |
FY |
|
Q1 |
Q2 |
Q3 |
Q4 |
FY |
|
Q1 |
|
Oral Health |
811 |
778 |
790 |
757 |
3,136 |
|
854 |
829 |
810 |
819 |
3,312 |
|
880 |
|
VMS |
405 |
411 |
410 |
414 |
1,640 |
|
422 |
435 |
407 |
432 |
1,696 |
|
416 |
|
Pain Relief |
724 |
681 |
636 |
611 |
2,652 |
|
662 |
641 |
628 |
633 |
2,564 |
|
661 |
|
Respiratory Health |
638 |
455 |
563 |
588 |
2,244 |
|
590 |
454 |
581 |
497 |
2,122 |
|
525 |
|
Digestive Health |
259 |
256 |
234 |
263 |
1,012 |
|
256 |
264 |
239 |
270 |
1,029 |
|
254 |
|
Therapeutic Skin Health and Other |
149 |
171 |
165 |
133 |
618 |
|
135 |
152 |
115 |
108 |
510 |
|
117 |
|
TOTAL |
2,986 |
2,752 |
2,798 |
2,766 |
11,302 |
|
2,919 |
2,775 |
2,780 |
2,759 |
11,233 |
|
2,853 |
|
Restated quarterly organic revenue growth by category (unaudited) |
|
|
|
||||||
|
|
2023 |
|
2024 |
|
2025 |
||||
|
% |
FY |
|
Q1 |
Q2 |
Q3 |
Q4 |
FY |
|
Q1 |
|
Oral Health |
10.6% |
|
10.6% |
9.1% |
8.2% |
10.6% |
9.6% |
|
6.6% |
|
VMS |
0.9% |
|
9.9% |
8.5% |
3.7% |
8.2% |
7.6% |
|
0.9% |
|
Pain Relief |
7.4% |
|
-4.8% |
-4.0% |
3.1% |
7.4% |
0.1% |
|
2.6% |
|
Respiratory Health |
11.7% |
|
-2.7% |
1.3% |
8.2% |
-2.6% |
1.0% |
|
0.7% |
|
Digestive Health |
5.8% |
|
2.2% |
5.2% |
9.0% |
5.8% |
5.5% |
|
2.3% |
|
Therapeutic Skin Health and Other |
8.8% |
|
7.4% |
10.7% |
0.7% |
24.2% |
9.8% |
|
10.4% |
|
TOTAL |
8.0% |
|
3.0% |
4.1% |
6.1% |
6.8% |
5.0% |
|
3.5% |
|
Restated quarterly reported revenue growth by category (unaudited) |
|
|
|
|
|||||
|
|
2023 |
|
2024 |
|
2025 |
||||
|
% |
FY |
|
Q1 |
Q2 |
Q3 |
Q4 |
FY |
|
Q1 |
|
Oral Health |
6.1% |
|
5.3% |
6.6% |
2.5% |
8.2% |
5.6% |
|
3.0% |
|
VMS |
-2.1% |
|
4.2% |
5.8% |
-0.7% |
4.3% |
3.4% |
|
-1.4% |
|
Pain Relief |
4.0% |
|
-8.6% |
-5.9% |
-1.3% |
3.6% |
-3.3% |
|
-0.2% |
|
Respiratory Health |
8.2% |
|
-7.5% |
-0.2% |
3.2% |
-15.5% |
-5.4% |
|
-11.0% |
|
Digestive Health |
1.9% |
|
-1.2% |
3.1% |
2.1% |
2.7% |
1.7% |
|
-0.8% |
|
Therapeutic Skin Health and Other |
1.5% |
|
-9.4% |
-11.1% |
-30.3% |
-18.8% |
-17.5% |
|
-13.3% |
|
TOTAL |
4.1% |
|
-2.2% |
0.8% |
-0.6% |
-0.3% |
-0.6% |
|
-2.3% |
Enquiries
|
Investors |
Media
|
||
|
Jo Russell |
+44 7787 392441 |
Zoë Bird |
+44 7736 746167 |
|
Rakesh Patel |
+44 7552 484646 |
Victoria Durman |
+44 7894 505730 |
|
Emma White |
+44 7823 523562 |
|
|
|
Email: corporate.media@haleon.com |
|||
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
